Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Expenses: 2009-2024

Historic Operating Expenses for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $239.4 million.

  • Vanda Pharmaceuticals' Operating Expenses rose 49.26% to $87.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.2 million, marking a year-over-year increase of 45.91%. This contributed to the annual value of $239.4 million for FY2024, which is 15.90% up from last year.
  • According to the latest figures from FY2024, Vanda Pharmaceuticals' Operating Expenses is $239.4 million, which was up 15.90% from $206.6 million recorded in FY2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Operating Expenses peaked at $248.1 million during FY2022, and registered a low of $206.6 million during FY2023.
  • For the 3-year period, Vanda Pharmaceuticals' Operating Expenses averaged around $231.4 million, with its median value being $239.4 million (2024).
  • In the last 5 years, Vanda Pharmaceuticals' Operating Expenses fell by 16.71% in 2023 and then rose by 15.90% in 2024.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Operating Expenses stood at $220.9 million in 2020, then rose by 2.53% to $226.5 million in 2021, then rose by 9.51% to $248.1 million in 2022, then fell by 16.71% to $206.6 million in 2023, then increased by 15.90% to $239.4 million in 2024.